Astral Laboratories complies with SEBI norms for FY26
Astral Laboratories Limited has reported full compliance with SEBI regulations for FY26, acquiring a material subsidiary. The secretarial audit confirmed adherence to governance standards, with no non-compliances or regulatory actions noted.

*this image is generated using AI for illustrative purposes only.
Astral Laboratories Limited has confirmed full compliance with the Securities and Exchange Board of India (SEBI) regulations for the financial year ended March 31, 2026. The Annual Secretarial Compliance Report, submitted to BSE Limited, certifies that the listed entity adhered to the provisions of the SEBI Act, 1992, and the Securities Contracts (Regulation) Act, 1956, along with relevant circulars and guidelines.
The report, issued by M/s Mahendra Khandelwal & Co., Practicing Company Secretaries, examined the company's documents, records, and filings made to the stock exchanges. It confirmed that Astral Laboratories maintained a functional website with timely dissemination of information and accurate web-links as required under Regulation 27(2) of the LODR Regulations. The company also adopted and updated all applicable policies under SEBI Regulations with board approval.
During the review period, the company acquired a wholly owned material subsidiary, Sriven Pharmachem India Private Limited. The secretarial audit verified that disclosures regarding this and other subsidiaries were made in accordance with regulatory requirements. Additionally, the performance evaluation of the Board, Independent Directors, and Committees was conducted as prescribed.
The audit confirmed that none of the directors were disqualified under Section 164 of the Companies Act, 2013. The company also complied with regulations concerning related party transactions, obtaining prior approval from the Audit Committee where necessary. No actions were taken by SEBI or stock exchanges against the entity, its promoters, or directors during the financial year.
Compliance Status
| Particulars | Compliance Status | Observations / Remarks by PCS |
|---|---|---|
| Secretarial Standards | YES | |
| Adoption and updation of Policies | YES | |
| Maintenance and disclosures on Website | YES | |
| Disqualification of Director | YES | |
| Details related to Subsidiaries | YES | Acquired wholly owned material subsidiary Sriven Pharmachem India Private Limited |
| Preservation of Documents | YES | |
| Performance Evaluation | YES | |
| Related Party Transactions | YES | |
| Disclosure of events or information | ||
| Prohibition of Insider Trading | YES | |
| Actions taken by SEBI or Stock Exchange | YES | |
| Resignation of statutory auditors | NA | No resignation of statutory auditors |
| Additional non-compliances | YES | No additional non-compliances observed |
| Employee Benefit Scheme Documents | NA | Company does not have any Employee Stock Option Scheme |
Historical Stock Returns for Astal Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +5.38% | +17.53% | -11.19% | -1.37% | -9.34% | +801.71% |
How will the acquisition of Sriven Pharmachem India Private Limited impact Astral Laboratories' revenue and market position in the upcoming fiscal year?
What strategic initiatives is the company pursuing following the full compliance certification to enhance shareholder value?
Are there any plans to introduce an Employee Stock Option Scheme (ESOS) in the future to attract and retain talent?


































